This is a snippet of the transcript, sign up to read more.
Indeed, the majority of a capital salesperson's total targeted compensation, if they meet their targets, is nearly $600,000. This includes a number of new robot sales, particularly sales in hospitals that do not yet have a robot. Although this number is declining in the United States, it remains significant overseas. It's the primary source of their income. They also receive a larger share from second system sales, which refer to any sale after the first one. They earn a substantial share from these additional system sales.
This is a snippet of the transcript, sign up to read more.
The clinical salesperson's role begins once the robot is installed. If the sale of the robot has been successful or there is an existing robot with enough availability for another surgeon to be recruited, it is the clinical salesperson's responsibility to recruit a surgeon. They guide them through their training, which includes case observations, simulation, lab training, post-lab cases, and the start of their cycle of cases.
This is a snippet of the transcript, sign up to read more.
The clinical salesperson is paid based on procedure growth. If their territory had 330 procedures and the growth expectation is 17%, they need to achieve a growth of 330 times 17% this quarter to meet their target. There are also other factors, like new instrument sales. For example, if a surgeon is trained in bariatric surgery and starts using the stapler, the clinical salesperson is paid based on the number of times the stapler is used. There are various procedural elements they are paid for, but the main focus is on quarterly procedure growth.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research